SCHEMBL825979

SCHEMBL825979

CC(=O)OC(=O)/C=C/C(=O)OC(C)=O

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.67
TSHR P16473 2/20 0.67
HCAR2 Q8TDS4 6/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
TDP1 Q9NUW8 3/20 0.45
HSD17B10 Q99714 2/20 0.45
ATM Q13315 1/20 0.35
LMNA P02545 3/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230634 1.00 ALDH1A1 (0.67) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL14152614 1.00 ALDH1A1 (0.67) ALDH1A1TSHRHCAR2KEAP1NFE2L2
Acetic Acid SCHEMBL29018083 0.94 ALDH1A1 (0.59) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL9474617 0.89 HCAR2 (0.56) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL8760880 0.89 HCAR2 (0.56) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL8760886 0.89 HCAR2 (0.56) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL11044892 0.87 HCAR2 (0.54) ALDH1A1TSHRHCAR2KEAP1NFE2L2
SCHEMBL1695596 0.85
SCHEMBL779039 0.85
SCHEMBL28977028 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002332-A1 SYSTEMS AND METHODS FOR FORMING BIOLOGICAL NANOWIRES AND APPLICATIONS THEREOF YALE UNIVERSITY (US) 2021-01-07 US disclosed
CN-108368075-A Modified cytotoxins and therapeutic uses thereof 加利福尼亚大学董事会 2018-08-03 CN disclosed
US-8859563-B2 Bicyclic pyrimidinones and uses thereof AVEXA LIMITED (AU) 2014-10-14 US disclosed
US-20120232035-A1 Bicyclic pyrimidinones and uses thereof AVEXA LIMITED (AU) 2012-09-13 US disclosed
US-8207334-B2 Bicyclic pyrimidinones and uses thereof AVEXA LIMITED (AU) 2012-06-26 US disclosed
US-8143268-B2 Bicyclic pyrimidinones and uses thereof AVEXA LIMITED (AU) 2012-03-27 US disclosed
EP-2114903-B1 BICYCLIC PYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2011-01-26 EP disclosed
US-20110009366-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2011-01-13 US disclosed
EP-2269992-A1 Bicyclic pyrimidinones for the treatment of viral infections Avexa Limited (AU) 2011-01-05 EP disclosed
US-20100316712-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS COMBINATORX, INCORPORATED (US) 2010-12-16 US disclosed
US-20100316712-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS COMBINATORX, INCORPORATED (US) 2010-12-16 US disclosed
US-20100168063-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-07-01 US disclosed
EP-2114903-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF Avexa Limited (AU) 2009-11-11 EP disclosed
WO-2008077188-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2008-07-03 WO disclosed
WO-2008079404-A2 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS COMBINATORX, INCORPORATED (US) 2008-07-03 WO disclosed
CN-1060775-C Fused tropane-derivatives as neurotransmitter reuptake inhibitors NEURORES AS (DK) 2001-01-17 CN disclosed
CN-1201461-A Fused tropane-derivatives as neurotransmitter reuptake inhibitors NEURORESEARCH A S (DK) 1998-12-09 CN disclosed
US-4390631-A INCUBATION WITH A WATER SOLUBLE IRON COMPOUND NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1983-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168063-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF TPMT, TYMP, DPYD ALDH1A1 337/4885TSHR 4293/4885HCAR2 1823/4885
US-20100316712-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS PARK7, SNCA, COMT ALDH1A1 397/4885TSHR 3446/4885HCAR2 2397/4885
US-20120232035-A1 Bicyclic pyrimidinones and uses thereof TPMT, TYMP, DPYD ALDH1A1 337/4885TSHR 4293/4885HCAR2 1823/4885
US-20110009366-A1 BICYCLIC PYRIMIDINONES AND USES THEREOF TPMT, TYMP, DPYD ALDH1A1 337/4885TSHR 4293/4885HCAR2 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.